Skip to main
KRYS
KRYS

Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech (KRYS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 80%
Buy 13%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Krystal Biotech Inc. has demonstrated robust financial performance, with $91.1 million in net revenue from Vyjuvek in the latest quarter, reflecting a 9% increase from the prior quarter and aligning with full-year projections of $290.5 million. The successful lung delivery and improved survival results from preclinical studies of their gene therapy platform indicate significant potential for future product development in the oncology space. Furthermore, the company's disciplined operational spending coupled with projected expansions and potential share repurchase programs positions it favorably as a growth-at-a-reasonable-price (GARP) investment opportunity.

Bears say

Krystal Biotech's stock outlook appears negative due to a decline in new reimbursement approvals, with projected decreases from 70 new adds in Q2 2024 to 50 by Q4 2024, highlighting challenges in sustaining revenue growth. Furthermore, despite increased competition thinning in certain gene therapy markets, the company faces potential setbacks linked to the inherent complexities of gene therapy development, including manufacturing difficulties and the unpredictable nature of clinical trial outcomes. Additionally, concerns related to patient recruitment in a competitive and rare disease landscape could further impede the company's ability to realize its financial objectives and advance its development pipeline effectively.

Krystal Biotech (KRYS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 13% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Krystal Biotech (KRYS) Forecast

Analysts have given Krystal Biotech (KRYS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, Krystal Biotech (KRYS) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Krystal Biotech (KRYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.